Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells $380,383.76 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,084 shares of Natera stock in a transaction on Monday, April 29th. The stock was sold at an average price of $93.14, for a total value of $380,383.76. Following the transaction, the chief executive officer now directly owns 226,235 shares of the company’s stock, valued at approximately $21,071,527.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, April 23rd, Steven Leonard Chapman sold 2,552 shares of Natera stock. The stock was sold at an average price of $91.38, for a total value of $233,201.76.
• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The stock was sold at an average price of $93.13, for a total value of $634,774.08.
• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The shares were sold at an average price of $88.96, for a total transaction of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $824,045.36.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $96.98 on Friday. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $11.86 billion, a price-to-earnings ratio of -25.59 and a beta of 1.38. The stock’s fifty day simple moving average is $90.56 and its 200 day simple moving average is $69.29. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $98.82.

Natera (NASDAQ:NTRA) last issued its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The business had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. As a group, sell-side analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Hedge funds have recently modified their holdings of the stock. YHB Investment Advisors Inc. acquired a new position in shares of Natera in the 1st quarter worth $36,000. RiverPark Advisors LLC purchased a new position in shares of Natera during the fourth quarter valued at $27,000. Principal Securities Inc. purchased a new position in shares of Natera during the fourth quarter valued at $32,000. Arcadia Investment Management Corp MI grew its holdings in shares of Natera by 47.8% during the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock valued at $49,000 after buying an additional 174 shares in the last quarter. Finally, Oliver Lagore Vanvalin Investment Group grew its holdings in shares of Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after buying an additional 389 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on NTRA. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday. Craig Hallum began coverage on shares of Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 target price for the company. Piper Sandler boosted their target price on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. The Goldman Sachs Group lifted their price target on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, April 15th. Finally, Raymond James cut Natera from a “strong-buy” rating to an “outperform” rating and lifted their price target for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.